RE: Diagnostics11 May 2023 14:11
HarChris, it is in a way but then look at the trading performance and it’s easy to see why. Ignore the cash as the market has clearly decided that that is all going to the dhsc.
In 2019 we took revenues of £11.5m and made a £3.4m loss.
2021 revenues of £93m and a loss of £5.7m (albeit impacted by the dispute heavily)
2022 revenues of £21m and £20m loss
2023 revenues based on Q1 run rate. - £6.8m (and that includes covid sales which will likely peter out completely)
What sort of loss are we going to book on revenues of £6.8m, given the increased (albeit now “right sized”) cost base?
Revenues 41% lower than pre covid.
It’s a staggeringly poorly run company based on that. All the contacts, learnings, new ideas, resource etc gained during the covid years and we’re looking at revenues almost half what they were pre covid. That is why the market has and continues to batter us. It’s painful for us who have almost lost the lot but looking at it objectively, it makes sense. The company has gone backwards at an alarming rate.